SUMATRIPTAN SUCCINATE INJECTION

The contract, awarded on July 20, 2026, under solicitation SPE2D226F3067, is a delivery order issued against the base indefinite-delivery, indefinite-quantity contract SPE2DX25D9822 to DMS PHARMACEUTICAL GROUP INC, identified by CAGE code 1UNB0, a small disadvantaged women-owned business. The total value of the order is $1,352.60 for four kilogram units of SUMATRIPTAN SUCCINATE INJECTION, identified by NSN 6505016724394 and NDCs 00173-0479-00 and 66993-0084-98. Delivery is required by the award date to USS CHARLESTON LCS 18 at FPO AP 96694 under FOB destination terms, meaning the contractor bears all transportation costs and risks until the goods are received at the military vessel’s location. Packaging must be shipped by the fastest traceable means, excluding parcel post, and all shipments and documents must be clearly marked with RDD, TCN, CLIN, PR number, manufacturer CAGE, and part number in block text for full traceability. Payment is processed through the Defense Finance and Accounting Service at Columbus, Ohio, under the Fast Pay Net 15 program with voucher tracking, and is tied to the accounting line BX: 97X4930 5CBX 001 2620 S33189. Inspection and acceptance occur at the destination by the government, and the contractor must comply with the DLA’s procedural notes C19 and C20 for acceptance standards and adherence to DoD unit of issue guidelines. No specific packaging, preservation, or barcoding standards such as MIL-STD-129R are cited in the documentation, though the delivery logistics align with general DoD shipping protocols. No contract clauses, special requirements, or evaluation factors beyond the basic delivery and payment terms are detailed, and the award appears to be a straightforward, single-line, firm-fixed-price transaction without options or alternates.